NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
https://www.zacks.com/stock/news/2335487/nvo-oral-obesity-pill-tops-wegovy-lly-vktx-gpcr-stocks-rise?cid=CS-ZC-FT-analyst_blog|industry_focus-2335487
Sep 12, 2024 - Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.
0
PFE or NVO: Which Is the Better Value Stock Right Now?
https://www.zacks.com/stock/news/2334754/pfe-or-nvo-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2334754
Sep 11, 2024 - PFE vs. NVO: Which Stock Is the Better Value Option?
0
Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug
https://www.zacks.com/stock/news/2334185/terns-stock-soars-on-positive-data-from-phase-i-study-of-obesity-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2334185
Sep 10, 2024 - TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant weight reduction compared to placebo.
0
Why you Should Buy the 200-day Dip in ARM, MSTR, VKTX
https://www.zacks.com/commentary/2333689/why-you-should-buy-the-200-day-dip-in-arm-mstr-vktx?cid=CS-ZC-FT-investment_ideas-2333689
Sep 09, 2024 - The 200-day moving average can provide some of the best long-term entry points. MicroStrategy, Coinbase, and Viking Therapeutics offer high reward-to-risk as they retreat to an important technical level.
0
Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals
https://www.zacks.com/stock/news/2333037/eli-lilly-s-weekly-insulin-shot-meets-two-late-stage-study-goals?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2333037
Sep 06, 2024 - Data from two late-stage studies show that LLY's once-weekly insulin injections achieved results that are similar to daily insulin shots.
0
Viking Surges 342% in the Past Year: How Should You Play the Stock?
https://www.zacks.com/stock/news/2330874/viking-surges-342-in-the-past-year-how-should-you-play-the-stock?cid=CS-ZC-FT-analyst_blog|most_popular_stocks-2330874
Sep 03, 2024 - VKTX stock continues to generate phenomenal returns, driven by encouraging development of its obesity and NASH drugs, which are nearing late-stage development.
0
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
https://www.fool.com/investing/2024/08/31/these-3-factors-could-make-eli-lilly-stock-better-/?source=iedfolrf0000001
Aug 31, 2024 - This competitive showdown just saw one of the players hit a couple of bumps.
0
GSK Stock Gains 18.5% Year to Date: Time to Buy, Sell or Hold?
https://www.zacks.com/stock/news/2328811/gsk-stock-gains-18-5-year-to-date-time-to-buy-sell-or-hold?cid=CS-ZC-FT-analyst_blog|rank_focused-2328811
Aug 29, 2024 - GSK's cheap valuation, reasonable stock price appreciation and bright growth potential indicate that investors should stay invested.
0
This GLP-1 Biotech Stock Could Give Novo Nordisk a Run for Its Money
https://www.fool.com/investing/2024/08/25/this-glp-1-biotech-stock-could-give-novo-nordisk-a/?source=iedfolrf0000001
Aug 25, 2024 - Its GLP-1 medicines are just one reason why it could threaten Novo Nordisk.
0
Top Research Reports for Microsoft, Novo Nordisk & Uber
https://www.zacks.com/commentary/2325287/top-research-reports-for-microsoft-novo-nordisk-uber?cid=CS-ZC-FT-research_daily-2325287
Aug 21, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp. (MSFT), Novo Nordisk A/S (NVO) and Uber Technologies, Inc. (UBER), as well as two micro-cap stocks Spok Holdings, Inc. (SPOK) and Willis Lease Finance Corp. (WLFC).
0